Literature DB >> 21298323

How to improve the immunogenicity of chemotherapy and radiotherapy.

Yuting Ma1, Rosa Conforti, Laetitia Aymeric, Clara Locher, Oliver Kepp, Guido Kroemer, Laurence Zitvogel.   

Abstract

Chemotherapy or radiotherapy could induce various tumor cell death modalities, releasing tumor-derived antigen as well as danger signals that could either be captured for triggering antitumor immune response or ignored. Exploring the interplay among therapeutic drugs, tumor cell death and the immune cells should improve diagnostic, prognostic, predictive, and therapeutic management of tumor. We summarized some of the cell death-derived danger signals and the mechanism for host to sense and response to cell death in the tumor microenvironment. Based on the recent clinical or experimental findings, several strategies have been suggested to improve the immunogenicity of cell death and augment antitumor immunity.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21298323     DOI: 10.1007/s10555-011-9283-2

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  34 in total

Review 1.  Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity.

Authors:  Xiaodan Qin; William D Denton; Leah N Huiting; Kaylee S Smith; Hui Feng
Journal:  Crit Rev Biochem Mol Biol       Date:  2020-07-07       Impact factor: 8.250

Review 2.  Immunogenic versus tolerogenic phagocytosis during anticancer therapy: mechanisms and clinical translation.

Authors:  A D Garg; E Romano; N Rufo; P Agostinis
Journal:  Cell Death Differ       Date:  2016-02-19       Impact factor: 15.828

Review 3.  Cancer immunotherapy via dendritic cells.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 4.  Immune microenvironments in solid tumors: new targets for therapy.

Authors:  Stephen L Shiao; A Preethi Ganesan; Hope S Rugo; Lisa M Coussens
Journal:  Genes Dev       Date:  2011-12-15       Impact factor: 11.361

Review 5.  Using immunotherapy to boost the abscopal effect.

Authors:  Wilfred Ngwa; Omoruyi Credit Irabor; Jonathan D Schoenfeld; Jürgen Hesser; Sandra Demaria; Silvia C Formenti
Journal:  Nat Rev Cancer       Date:  2018-02-16       Impact factor: 60.716

Review 6.  Current status of interleukin-10 and regulatory T-cells in cancer.

Authors:  Kristen L Dennis; Nichole R Blatner; Fotini Gounari; Khashayarsha Khazaie
Journal:  Curr Opin Oncol       Date:  2013-11       Impact factor: 3.645

Review 7.  Adenosine can thwart antitumor immune responses elicited by radiotherapy : Therapeutic strategies alleviating protumor ADO activities.

Authors:  Peter Vaupel; Gabriele Multhoff
Journal:  Strahlenther Onkol       Date:  2016-03-09       Impact factor: 3.621

Review 8.  Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.

Authors:  François Bertucci; Anthony Gonçalves
Journal:  Curr Oncol Rep       Date:  2017-08-10       Impact factor: 5.075

Review 9.  Myeloid Cells as Targets for Therapy in Solid Tumors.

Authors:  Tiziana Cotechini; Terry R Medler; Lisa M Coussens
Journal:  Cancer J       Date:  2015 Jul-Aug       Impact factor: 3.360

Review 10.  At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok
Journal:  J Leukoc Biol       Date:  2013-05-10       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.